Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
High-rolling investors have positioned themselves bearish on Eli Lilly and Co (NYSE:LLY), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in LLY often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 12 options trades for Eli Lilly and Co. This is not a typical pattern.
The sentiment among these major traders is split, with 41% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $50,300, and 11 calls, totaling $569,034.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $630.0 to $960.0 for Eli Lilly and Co over the recent three months.
In today's trading context, the average open interest for options of Eli Lilly and Co stands at 451.5, with a total volume reaching 20.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly and Co, situated within the strike price corridor from $630.0 to $960.0, throughout the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | CALL | TRADE | BULLISH | 08/23/24 | $49.8 | $43.0 | $48.24 | $900.00 | $144.7K | 2 | 0 |
LLY | CALL | TRADE | BEARISH | 07/05/24 | $55.9 | $48.95 | $51.22 | $850.00 | $76.8K | 95 | 0 |
LLY | CALL | SWEEP | BEARISH | 08/16/24 | $24.45 | $22.5 | $23.2 | $950.00 | $69.5K | 943 | 0 |
LLY | PUT | TRADE | BEARISH | 06/20/25 | $50.3 | $47.85 | $50.3 | $800.00 | $50.3K | 51 | 0 |
LLY | CALL | TRADE | NEUTRAL | 08/16/24 | $78.45 | $71.8 | $75.63 | $850.00 | $45.3K | 840 | 0 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $958.8.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly and Co options trades with real-time alerts from Benzinga Pro.
Posted In: LLY